What is it about?
Anamorelin hydrochloride was evaluated in Japanese patients with advanced gastrointestinal cancer and cachexia in a non-randomized single-arm study. The proportion of patients who responded to treatment was 63.3%, with a least square mean ± SE change in lean body mass and body weight from baseline of 1.89 ± 0.36 kg and 1.41 ± 0.61 kg, respectively. Appetite-related questions on the QoL questionnaire showed that anamorelin improved appetite. Adverse events occurred in 79.6% of patients, and the most common treatment-related adverse events were increased γ-glutamyl transpeptidase (8.2%), diabetes mellitus (6.1%), hyperglycemia (6.1%), and prolonged QRS complex (6.1%).
Photo by Christina Branco on Unsplash
Why is it important?
We showed a positive effect of anamorelin on lean body mass, body weight, and anorexia that was comparable to the previous data in patients with lung cancer.
Read the Original
This page is a summary of: A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia, Cancer, August 2019, Wiley, DOI: 10.1002/cncr.32406.
You can read the full text:
PMC full text
A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia Satoshi Hamauchi, Junji Furuse, Toshimi Takano, Yoshinori Munemoto, Ken Furuya, Hideo Baba, Manabu Takeuchi, Yasuhiro Choda, Takashi Higashiguchi, Tateaki Naito, Kei Muro, Koichi Takayama, Shusuke Oyama, Toru Takiguchi, Naoyuki Komura, Kazuo Tamura Cancer, August 2019, Wiley DOI: 10.1002/cncr.32406
The following have contributed to this page